GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

Rating:
Buy ACHN
down 62.91 %

Achillion Pharmaceuticals, Inc. (ACHN) rated Buy by BofA/Merrill

Posted on: Wednesday,  Sep 19, 2012  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Buy Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 09/19/2012, when the stock price was $9.33. Since then, Achillion Pharmaceuticals,
Inc. has lost 62.92% of its value until BofA/Merrill rated ACHN Underperform on 09/30/2013, when the price was $3.46.
If you would have followed this BofA/Merrill's recommendation on ACHN, you would have lost 62.91% of your investment in 376 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

BofA/Merrill
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/30/2013 8:25 AM Sell
None
3.46
as of 12/31/2012
1 Week down  -7.18 %
1 Month up  2.82 %
3 Months down  -22.98 %
1 YTD down  -14.14 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/19/2012 8:25 AM Buy
None
9.33

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy